ViaLase and the John A. Moran Eye Center Announce Research Partnership to Accelerate Glaucoma Research and Innovation [Yahoo! Finance]
Doximity, Inc. Class A (DOCS)
Company Research
Source: Yahoo! Finance
Crandall Center for Glaucoma Innovation ALISO VIEJO, Calif., December 10, 2024 BUSINESS WIRE ViaLase, Inc. , a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced a research partnership with the John A. Moran Eye Center at the University of Utah (Moran Eye Center), home to the renowned Alan S. Crandall Center for Glaucoma Innovation (Crandall Center). The collaboration will explore aqueous outflow dynamics of ViaLase's novel ViaLase laser procedure, utilizing Moran's state-of-the-art iPerfusion technology. The ViaLase laser procedure delivers precise femtosecond laser pulses with micron-accurate image guidance to create apertures through the trabecular meshwork (TM) and into Schlemm's canal. Utilizing perfusion technology to study how aqueous humor drains from the eye through the conventional outflow pathway, researchers will explore the effect of creating multiple channels as well as the opti
Show less
Read more
Impact Snapshot
Event Time:
DOCS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DOCS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DOCS alerts
High impacting Doximity, Inc. Class A news events
Weekly update
A roundup of the hottest topics
DOCS
News
- Healthcare In 2025: A Year Of Practical AI, Remote Care And Patient-Centered Solutions [Forbes]Forbes
- 4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow [Yahoo! Finance]Yahoo! Finance
- Doximity (DOCS) Ascends But Remains Behind Market: Some Facts to Note [Yahoo! Finance]Yahoo! Finance
- Doximity, Inc. (NASDAQ: DOCS) is now covered by analysts at Stephens. They set an "equal weight" rating and a $55.00 price target on the stock.MarketBeat
- DOXIMITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Doximity, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewswire
DOCS
Earnings
- 11/7/24 - Beat
DOCS
Sec Filings
- 11/15/24 - Form 4
- 11/15/24 - Form 4
- 11/14/24 - Form SC
- DOCS's page on the SEC website